Futura Medical (GB:FUM) has released an update.
Futura Medical PLC, a consumer healthcare company known for Eroxon®, has announced a change in its Nominated Adviser and Joint Broker to Panmure Liberum Limited following a merger. The company specializes in the development and international commercialization of innovative sexual health products, with Eroxon® being a standout, topically applied treatment for Erectile Dysfunction that works rapidly and is available over-the-counter. Futura has established partnerships for distribution in key markets, including with Haleon in the US and Cooper Consumer Health in Europe.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.